We spoke with Ben Thompson (University of Waterloo, Waterloo, ON, Canada) about neuroplasticity, and the relevance of visual plasticity in the treatment of amblyopia.
Questions
- Could you give us a brief overview of neuroplasticity and its biological basis? (00:13)
- What manifestations of visual plasticity exist in the visual cortex of adults? (01:11)
- What is the relevance of visual plasticity in the treatment of amblyopia? (02:09)
Speaker Disclosure: Ben Thompson discloses the following: Two patents relating to binocular amblyopia treatment that have been licensed by Novartis. Two patents relating to assessment of children’s vision and co-founder of Objective Acuity, a company commercializing this technology. Paid consultancy for Novartis and Objective Acuity.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of ARVO 2021.
